← ANALYST RATINGS · TIPRANKS
Anavex Life Sciences (AVXL): analyst forecast and price target
Analyst consensus
0 Buy0 Hold0 Sell
Ratings of 0 analysts in the last 3 months12-month forecast
Based on 0 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $1.31.
Analyst ratings 2
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | +14.5% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Hold | +14.5% | Upgrade | 06.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | +14.5% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | +14.5% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | +14.5% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | +14.5% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | +52.7% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Sell | +52.7% | Downgrade | 01.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | +52.7% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | +52.7% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Hold | +52.7% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | +52.7% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 | Hold | +90.8% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 | Hold | +90.8% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 | Hold | +90.8% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 | Hold | +90.8% | Upgrade | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 | Hold | +90.8% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 | Hold | +90.8% | Reiterated | 29.09.26on TipRanks Sep 28 23:05 | — | |
| Seema Sheoran★★★★★★★★★★#8280 · hits 33% · avg +0.9% | Rodman & Renshaw | $20.00 | Buy | +1,426.7% | Initiated | 04.05.26on TipRanks May 5 14:05 | +3.1%next day −2.3% · 5 days −8.0% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $20.00 | Buy | +1,426.7% | Reiterated | 31.03.26on TipRanks 06:35 | +6.0%next day +0.2% · 5 days −4.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Anavex Life Sciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Anavex Life Sciences
- CEO: Terrie Kellmeyer
- Employees: 34
- 630 5th Avenue, New York City, NY, 10111, US
- www.anavex.com
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Data from the stock’s TipRanks forecast page, read 232 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗